PDCD1 and neoplasm: Molecular biomarkers such as TMB (tumor mutation burden), CTLA-4 (cytotoxic T lymphocyte-associated antigen-4), PD-1/PDL1 (Programmed cell death 1 ligand 1) have been gradually incorporated into clinical guidelines.